# Beta-Blockers

β-blockers are competitive (often highly selective) antagonists of β-adrenoreceptors. They are subclassified into into selective and non-selective agents:
* Selective (β<sub>1</sub> antagonism) (BEAM)
    * Bisoprolol
    * Esmolol
    * Atenolol
    * Metoprolol
* Non-selective (β<sub>1</sub> and β<sub>2</sub> antagonism)
    * Propranolol
    * Sotalol
    * Timolol
* Non-selective (β & α antagonism)
    * Carvedilol
    * Labetaolol


##Indications
* Cardio
    * Angina
    * Arrythmia
        * Rate-control in AF
        * Paroxysmal SVT
        * Sinus tachycardia from ↑ catecholamines
    * Cardiac Failure
    * Secondary prevention for MI


* Vascular
    * Hypertension (2<sup>nd</sup> line), though are useful for aggressive control of BP
    * Hypotensive anaesthesia
    * Attenuate hypertensive response to laryngoscopy


* Non-CVS
    * Thyrotoxicosis
    * Glaucoma (topically)
    * Anxiety
    * Migraine prophylaxis



##Common Features
|Property|Action|
|--|--|
|**Kinetics**|Variability primarily due to lipid solubility. Poor lipid solubility gives poor gut absorption and minimises need for hepatic metabolism. Lipid soluble agents will have CNS effects and be excreted in breast milk
|**Respiratory**|Bronchospasm
|**CVS**|↓ Inotropy, ↓ HR, ↓MVO<sub>2</sub>, ↓ BP, ↑ SVR (β<sub>2</sub> effect), worsen arrhythmia
|**CNS**|Tiredness, nightmares, and sleep disturbance with lipid soluble agents. ↓ IOP
|**Metabolic**|↓ Insulin release and blunted hypoglycaemic response (β<sub>2</sub> effect)
|**Interactions**|Contraindicated with cardioselective Ca<sup>2+</sup> channel blockers due to extreme ↓ HR & ↓ inotropy|

##Comparison of Beta Blockers
|Property|Esmolol|Metoprolol|Atenolol|Propranolol|Labetalol|
|--|--|
|**Class**|Cardioselective|Cardioselective|Cardioselective|Non-selective|Non-selective|
|**Uses**|Short-term treatment of tachyarrythmia and HTN|MI, HTN, migraine, thyrotoxicosis|HTN, angina, tachyarrhythmias, acute MI|HTN, Angina, dysrrythmia, essential tremor, anxiety HOCM, phaeochromocytoma, migraine, oesophageal varicies|HTN, MI|
|**Presentation**|Clear, colourless solution|Clear, colourless solution, 50mg Tablet.|25/50/100mg tablets, syrup, colourless solution.|Tablets and solution at 1mg.ml<sup>-1</sup>|Tablets and solution at 5mg.ml<sup>-1</sup>
|**Route of Administration**|IV|PO/IV|PO/IV|PO/IV|PO/IV|
|**Dosing**|50-200μg.kg<sup>-1</sup>.min<sup>-1</sup>|IV: 1mg boluses PO: 12.5-100mg BD|PO: 50-100mg daily IV: 2.5mg IV up to 10mg|PO: 10-100mg BD/TDS IV: 1mg boluses titrated to response|PO: 100-800mg BD<br> IV: 10-20mg IV bolus, followed by 20-80mg Q30min up to 300mg. Alternatively by infusion at 1-2mg.min<sup>-1</sup>|
|**Absorption**|IV only|50% bioavailability, improves with regular use|45% PO bioavailability|30% bioavailability|Highly variable bioavailability: 10-80%|
|**Distribution**|60% protein bound|20% protein bound. Lipid soluble|5% protein bound|95% protein bound|50% protein bound|
|**Metabolism**|RBC esterases to an inactive metabolite and methyl alcohol. t<sub>1/2</sub> of 10 minutes|Hepatic with genetic variability in t<sub>1/2</sub> of active metabolites|Minimal metabolism - dose reduce in renal failure|Hepatic to active and inactive metabolites|Hepatic to inactive metabolites|
|**Elimination**|||Renal elimination of active drug|Renal elimination of metabolites|Renal elimination of inactive metabolites|
|**CVS**|Venous irritant||||↓ SVR, ↓ HR, ↓ CO, ↓ BP (typically ~20%)|

---
##References
Dr. Podcast - Antihypertensives
Peck and Hill
Smith Scarth Sasada